

# The Effect of Hydrogen Sulfide Donors on Lipopolysaccharide-Induced Formation of Inflammatory Mediators in Macrophages

Matthew Whiteman,<sup>1</sup> Ling Li,<sup>2</sup> Peter Rose,<sup>2</sup> Choon-Hong Tan,<sup>3</sup>  
David B. Parkinson,<sup>4</sup> and Philip K. Moore<sup>2</sup>

## Abstract

The role of hydrogen sulfide (H<sub>2</sub>S) in inflammation is controversial, with both pro- and antiinflammatory effects documented. Many studies have used simple sulfide salts as the source of H<sub>2</sub>S, which give a rapid bolus of H<sub>2</sub>S in aqueous solutions and thus do not accurately reflect the enzymatic generation of H<sub>2</sub>S. We therefore compared the effects of sodium hydrosulfide and a novel slow-releasing H<sub>2</sub>S donor (GYY4137) on the release of pro- and antiinflammatory mediators in lipopolysaccharide (LPS)-treated murine RAW264.7 macrophages. For the first time, we show that GYY4137 significantly and concentration-dependently inhibits LPS-induced release of proinflammatory mediators such as IL-1 $\beta$ , IL-6, TNF- $\alpha$ , nitric oxide ( $\bullet$ NO), and PGE<sub>2</sub> but increased the synthesis of the antiinflammatory chemokine IL-10 through NF- $\kappa$ B/ATF-2/HSP-27-dependent pathways. In contrast, NaHS elicited a biphasic effect on proinflammatory mediators and, at high concentrations, increased the synthesis of IL-1 $\beta$ , IL-6, NO, PGE<sub>2</sub> and TNF- $\alpha$ . This study clearly shows that the effects of H<sub>2</sub>S on the inflammatory process are complex and dependent not only on H<sub>2</sub>S concentration but also on the rate of H<sub>2</sub>S generation. This study may also explain some of the apparent discrepancies in the literature regarding the pro- *versus* antiinflammatory role of H<sub>2</sub>S. *Antioxid. Redox Signal.* 12, 1147–1154.

## Introduction

**H**YDROGEN SULFIDE (H<sub>2</sub>S) is a pungent gas that is formed endogenously in mammalian tissues from the amino acids cysteine and homocysteine by pyridoxal-5'-phosphate-dependent enzymes such as cystathionine- $\gamma$ -lyase (CSE; E.C. 4.4.1.1) and cystathionine- $\beta$ -synthetase (CBS; E.C. 4.2.1.22) (12, 28). To date, H<sub>2</sub>S biosynthesis has been identified in a variety of mammalian tissues, notably in the brain, heart, and the gastrointestinal tract, as well as in isolated vascular smooth muscle and endothelial cells and neurons (19, 29). A number of possible physiologic and pathophysiologic roles for this gas have been put forward, and a range of potential therapeutic uses of this gas has been proposed (10, 21, 28).

It is now becoming increasingly apparent that H<sub>2</sub>S exerts complex effects on inflammation. For example, we previously reported that administration of sodium hydrosulfide (NaHS), a "fast releasing" H<sub>2</sub>S donor, to mice (9) provokes an inflammatory reaction, as evidenced by increased liver and lung

myeloperoxidase (MPO) activity (a marker for tissue leukocyte infiltration) and histologically by the presence of accumulated leukocytes extravascularly in the lung. These results suggest a proinflammatory effect of H<sub>2</sub>S, as does the finding that DL-propargylglycine (PAG), an irreversible inhibitor of CSE, exhibits antiinflammatory activity in a range of animal models of inflammation (2, 4, 14).

However, NaHS also has been reported to inhibit leukocyte adhesion to gastric mucosal blood vessels (30), which may be suggestive of an antiinflammatory effect. In addition, H<sub>2</sub>S "scavenges" proinflammatory oxidants such as nitric oxide ( $\bullet$ NO), peroxyxynitrite (ONOO $\bullet$ ), hypochlorous acid (HOCl) (25, 26), superoxide, and hydrogen peroxide (3, 6, 15); such effects might be expected to alleviate inflammation. Finally, S-diclofenac (an H<sub>2</sub>S-releasing derivative of the nonsteroidal antiinflammatory drug, diclofenac) exhibits more-pronounced antiinflammatory activity in endotoxic shock (11) and against carrageenan-induced hindpaw edema (18) in the rat than does diclofenac. In each case, evidence has been presented that the

<sup>1</sup>Peninsula Medical School, University of Exeter, St. Luke's Campus, Exeter, Devon; and <sup>2</sup>Pharmaceutical Science Research Division, King's College, University of London, London, England.

<sup>3</sup>Department of Chemistry, National University of Singapore, Singapore.

<sup>4</sup>Peninsula Medical School, University of Plymouth, Tamar Science Park, Plymouth, Devon, England.

augmented antiinflammatory action of this compound is secondary to the release of H<sub>2</sub>S from the parent molecule.

Recently, this group reported that GYY4137 [morpholin-4-ium 4-methoxyphenyl(morpholino) phosphinodithioate] releases H<sub>2</sub>S slowly over a period of hours both *in vitro* and after injection in the rat *in vivo* (13). In addition, GYY4137 exhibits antiinflammatory activity *in vivo*, as evidenced by a reduction in the lipopolysaccharide (LPS)-induced increase in plasma proinflammatory cytokines (TNF- $\alpha$ , IL-1 $\beta$ , IL-6), nitrite/nitrate, C-reactive protein, and L-selectin in the conscious rat (12).

H<sub>2</sub>S exerts complex and, at times, opposing effects on inflammation in whole animals. One possible explanation for these discrepant data may be the choice of H<sub>2</sub>S donor used in these various studies. The available H<sub>2</sub>S donors release H<sub>2</sub>S at different rates and therefore give rise to different concentrations of the gas over different time periods. In the present work, we therefore compared the effect on LPS-induced proinflammatory enzyme/metabolite generation in cultured RAW 264.7 macrophages of the fast-releasing H<sub>2</sub>S donor, NaHS, and the slow-releasing H<sub>2</sub>S donor, GYY4137.

## Materials and Methods

### Culture of RAW 264.7 cells

The murine RAW 264.7 macrophage cell line was purchased from the American Type Culture Collection (Rockville, MD). RAW 264.7 cells were chosen for the present experiments, as macrophages play an integral part in the etiology of inflammation, and their response to LPS has been intensively characterized. Cells were cultured in complete Dulbecco's Modified Eagle Medium (containing 10% vol/vol fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin, pH 7.4) at 37°C in 5% CO<sub>2</sub> until ~70–80% confluence. Cells (0.2 × 10<sup>6</sup> cells/ml) were then cultured overnight before the addition of either NaHS or GYY4137 (both 0–1,000  $\mu$ M) along with an appropriate volume of vehicle, as well as LPS (1  $\mu$ g/ml). After a further 24-h incubation period, medium or cells or both were harvested and assayed, as described later.

For some experiments, GYY4137 was prepared in aqueous solution and left unstoppered at room temperature for 5 days. Such "decomposed GYY4137" failed to release H<sub>2</sub>S on incubation and was therefore used as a control to assess the role of released H<sub>2</sub>S in the effect of GYY4137. To determine whether H<sub>2</sub>S donors were cytotoxic in these cells, cellular viability was assessed by using 3-(4,5-dimethyl-2-yl)-2,5-diphenyltetrazolium bromide (MTT), as described (25).

### Assay of CSE/CBS enzyme activity and measurement of H<sub>2</sub>S

CSE and CBS recombinant protein (12.5  $\mu$ g; Abnova Ltd, Taiwan) were added to Tris-HCl buffer (100 mM; pH 7.4; 25°C) containing L-cysteine (10  $\mu$ M) and pyridoxal phosphate (10  $\mu$ M). H<sub>2</sub>S generation was detected by using a World Precision Instruments H<sub>2</sub>S-selective membrane and electrode (ISO-H2S-2; 2 mm, Sarasota, FL), with four-channel TBR4100-416 radical detector equipped with a Lab-Trax-4 four-channel data-acquisition system, as described previously (13). In separate experiments, H<sub>2</sub>S generation from added NaHS (1  $\mu$ M) and GYY4137 (100  $\mu$ M) in phosphate-buffered saline (3 ml; pH 7.4; 25°C) also was determined for comparison.

### Assay of nitrite, PGE<sub>2</sub>, H<sub>2</sub>S, IL-1 $\beta$ , TNF- $\alpha$ , IL-6, and IL-10 in medium

Levels of nitrite (NO<sub>2</sub><sup>-</sup>), PGE<sub>2</sub>, IL-1 $\beta$ , TNF- $\alpha$ , IL-6, and IL-10 were assayed in culture media. NO<sub>2</sub><sup>-</sup> was determined spectrophotometrically in aliquots of culture medium by using the Griess reagent, as described elsewhere (17). H<sub>2</sub>S in culture medium was measured spectrophotometrically by using the methylene blue assay, as described previously (9). IL-1 $\beta$ , TNF- $\alpha$ , IL-6, and IL-10 were assayed with ELISA, according to the manufacturer's instructions (R&D Systems, Inc., Minneapolis, MN). PGE<sub>2</sub> production was determined by using a PGE<sub>2</sub> enzyme immunoassay kit according to the manufacturer's instructions (Cayman, Ann Arbor, MI).

### Assay of NF- $\kappa$ B, HSP-27, and pATF-2 in cells

RAW 264.7 cells treated as described earlier were harvested, and the nuclear proteins extracted by using a nuclear extraction kit (Panomics, Fremont, CA), as described previously (11, 27). The nuclear extracts (10–20  $\mu$ g) were assayed in duplicate for activity by using TransAM NF- $\kappa$ B p65 assay kit (Active Motif, Carlsbad, CA), according to the manufacturer's instructions. Data are shown as relative light units (RLUs). Phosphorylation of HSP-27 and ATF-2 was assayed quantitatively by using Fast Activated Cell-based ELISA (FACE) HSP27(S82) and ATF2 (T71) kits (Active Motif Europe, Rixensart, Belgium), again according to the manufacturer's instruction.

### Chemicals and data analysis

GYY4137 was synthesized chemically by Dr. Choon-Hong Tan (Department of Chemistry, National University of Singapore), as described previously (13). Analytic kits were purchased from suppliers, as stated in the text. All drugs and chemicals were obtained from Sigma Chemical Company (Peele, U.K.). Data are shown as mean  $\pm$  SEM, with the number of observations indicated in parentheses. Statistical analysis was with one-way ANOVA followed by the *post hoc* Tukey test. A *p* value of < 0.05 was taken to indicate a statistically significant difference.

## Results

### Release of H<sub>2</sub>S from CSE/CBS, GYY4137, and NaHS *in vitro*

Incubation of either recombinant CSE or CBS enzyme with added L-cysteine and cofactor resulted in the time-dependent formation of H<sub>2</sub>S (Fig. 1A). CSE produced more H<sub>2</sub>S than CBS under these experimental conditions, with the amount generated still increasing at 180 s for both enzymes. Incubation of GYY4137 in aqueous solution also resulted in the release of similar amounts of H<sub>2</sub>S over a similar time frame (Fig. 1C). In contrast, release of H<sub>2</sub>S from incubated NaHS was much greater (~200-fold) and occurred over a much shorter time period (Fig. 1B).

### Effect of GYY4137 and NaHS on LPS-evoked PGE<sub>2</sub> and NO<sub>2</sub><sup>-</sup> formation

As expected (17), treatment of RAW 264.7 cells with LPS resulted in a significant increase in both PGE<sub>2</sub> and NO<sub>2</sub><sup>-</sup>




FIG. 1. Time course of *in vitro* enzymatic formation of H<sub>2</sub>S from L-cysteine by recombinant CSE and CBS (A) and spontaneous H<sub>2</sub>S release from incubated NaHS (1 μM, B) and GYY4137 (100 μM, C). H<sub>2</sub>S was detected amperometrically. Results show representative traces from at least four separate experiments.


concentrations in the medium. Treatment of LPS-exposed RAW 264.7 cells with GYY4137 (0–1,000 μM) resulted in a concentration-dependent inhibition of the biosynthesis of both PGE<sub>2</sub> (Fig. 2A) and NO<sub>2</sub><sup>-</sup> (Fig. 2B), with half-maximal inhibitory concentration (IC<sub>50</sub>) values of 210.9 ± 4.5 and 127.2 ± 32.4 μM (*n* = 5). Furthermore, similar treatment of RAW 264.7 cells with GYY4137 (100 μM) resulted in a significant increase in the concentration of H<sub>2</sub>S detected in the culture medium after 24 h (29.2 ± 1.8 μM, *c.f.* 1.6 ± 0.7 μM; *n* = 5; *p* < 0.05). Inhibition of LPS-evoked formation of both PGE<sub>2</sub> and NO<sub>2</sub><sup>-</sup> was >90% inhibition at the higher concentration (>500 μM) of GYY4137 used. “Decomposed GYY4137” did not significantly affect LPS-evoked formation of either PGE<sub>2</sub> or NO<sub>2</sub><sup>-</sup> (*p* > 0.05). In contrast, the effect of NaHS (0–1,000 μM) on LPS-evoked PGE<sub>2</sub> formation in cultured RAW 264.7 cells was seemingly biphasic, with modest inhibition (~40% of control values) apparent at lower concentrations (*i.e.*, 200 μM). This effect was gradually reversed as the concentration of NaHS was increased, with no significant effect noted at concentrations in excess of 500 μM (Fig. 2A and B). In contrast, NaHS (0–1,000 μM) did not significantly affect LPS-evoked NO<sub>2</sub><sup>-</sup> formation, although a trend toward activation of LPS-evoked NO<sub>2</sub><sup>-</sup> generation was evident at higher concentrations. Interestingly, treatment of RAW 264.7 cells with NaHS (100 μM) did not increase the concentration of H<sub>2</sub>S detected in the culture medium after 24 h (1.8 ± 0.6 μM, *c.f.* 1.6 ± 0.8 μM; *n* = 5; *p* > 0.05). Control experiments showed that neither GYY4137 (1 mM) nor NaHS (1 mM) induced a significant loss of cell viability (percentage)

assessed by using the MTT assay; GYY4137, 98.3 ± 2.5%; NaHS, 95.4 ± 8.3%; vehicle-treated control cells, 102.9 ± 3.2% (all *n* = 5; *p* > 0.05).

#### Effect of GYY4137 and NaHS on LPS-evoked cytokine formation

Treatment of RAW 264.7 cells with LPS also resulted in a significant increase in both TNF-α and IL-1β concentrations in the medium. Co-treatment of LPS-exposed RAW 264.7 cells with GYY4137 (0–1,000 μM) resulted in a concentration-related inhibition of the formation of both TNF-α (Fig. 3A) and IL-1β (Fig. 3B) with IC<sub>50</sub> values of 70.4 ± 4.4 and 134.1 ± 10.1 μM (*n* = 5), respectively. In both cases, substantial inhibition was achieved at higher concentrations of GYY4137 (>500 μM). In contrast, NaHS (0–1,000 μM) did not inhibit the biosynthesis of either cytokine (Fig. 3A and B). Indeed, at the highest concentration of NaHS used, a significant enhancement of the LPS-evoked generation of both TNF-α and IL-1β.

Because GYY4137 elicited concentration-dependent inhibition of LPS-induced TNF-α and IL-1β formation, we also investigated the effect of this H<sub>2</sub>S donor on the generation of both proinflammatory IL-6 and antiinflammatory IL-10 in cultured RAW 264.7 cells under identical experimental conditions. GYY4137 (10–500 μM) inhibited the LPS-evoked increase in IL-6 concentration (Fig. 4A), while potentiating the LPS-evoked increase in biosynthesis of IL-10 (Fig. 4B). Even the lowest concentration of GYY4137 used (*i.e.*, 10 μM) reduced IL-6 formation by >50%. In comparison, NaHS



**FIG. 2.** Effect of NaHS (black columns) and GYY4137 (open columns) on LPS (1 μg/ml)-evoked release of PGE<sub>2</sub> (A) and nitrite (B) in incubated (24 h) RAW 264.7 cells. Results show concentration of PGE<sub>2</sub> (ng/ml) or nitrite (micromolar) and are expressed as mean ± SEM; *n* = 5; \**p* < 0.05 (c.f. LPS group); +*p* < 0.05 (c.f. saline group); ANOVA plus *post hoc* Tukey test.


(100 μM) also inhibited IL-6 production but failed to affect the generation of IL-10 (Fig. 4A and B).

#### Effect of GYY4137 on phosphorylation of HSP 27 and ATF-2

Incubation of RAW 264.7 cells with LPS resulted in marked phosphorylation of both HSP27 and ATF-2 (Fig. 5A and B). In both cases, inclusion of GYY4137 (10–500 μM) significantly inhibited LPS-evoked phosphorylation. GYY4137 was particularly effective as an inhibitor of HSP-27 phosphorylation with an IC<sub>50</sub> of 14.0 ± 1.1 μM (*n* = 5). Similarly, relatively low concentrations of GYY4137 (10–100 μM) also inhibited ATF-2 phosphorylation, with an IC<sub>50</sub> of 35.1 ± 6.7 μM (*n* = 5). However, in this case, inhibition declined and was partially reversed at the highest concentration (500 μM).

#### Effect of GYY4137 and NaHS on LPS-evoked activation of NF-κB

Treatment of RAW 264.7 cells with LPS resulted in a significant increase in NF-κB activation. Treatment of LPS-




**FIG. 3.** Effect of NaHS (black columns) and GYY4137 (open columns) on LPS (1 μg/ml)-evoked release of TNF-α (A) and IL-1β (B) in incubated (24 h) RAW 264.7 cells. Results show concentration of each cytokine (ng/ml) and are expressed as mean ± SE; *n* = 5; \**p* < 0.05 (c.f. LPS group); +*p* < 0.05 (c.f. saline group); ANOVA plus *post hoc* Tukey test.

exposed RAW 264.7 cells with GYY4137 (0–1,000 μM) caused a concentration-related inhibition of the activation of NF-κB (Fig. 5), with an IC<sub>50</sub> value of 214.8 ± 10.0 μM (*n* = 5). Interestingly, the effect of NaHS (0–1,000 μM) was biphasic, with lower concentrations (100–200 μM) promoting NF-κB activation, whereas a high concentration (1,000 μM) caused inhibition (Fig. 6).

## Discussion


The role of H<sub>2</sub>S as an inflammatory mediator is clearly complex. The vast majority of studies carried out used simple sulfide salts such as sodium hydrosulfide (NaHS) and sodium sulfide (Na<sub>2</sub>S), which generate H<sub>2</sub>S instantaneously in aqueous solutions. Indeed, we show here, by using an H<sub>2</sub>S-selective probe, that NaHS releases large amounts of H<sub>2</sub>S over a period of a few seconds. Although undoubtedly useful in that these salts are convenient and circumvent the necessity for the somewhat more-complex preparation of authentic H<sub>2</sub>S gas solutions, the manner in which cells and tissues are



**FIG. 4.** Effect of NaHS (black column) and GYY4137 (open columns) on LPS (1 µg/ml)-evoked release of IL-6 (A) and IL-10 (B) in incubated (24 h) RAW 264.7 cells. Saline-treated control cells are shown by the grey column. Results show concentration of cytokines (pg/ml) and are expressed as mean ± SEM;  $n = 5-9$ ; \* $p < 0.05$  (c.f. LPS group);  $^+p < 0.05$  (c.f. saline group); ANOVA plus *post hoc* Tukey test.

exposed to the gas *via* NaHS, Na<sub>2</sub>S, and H<sub>2</sub>S gas solutions is unlikely to reflect accurately either the physiologic or the pathophysiologic situation. Thus, these approaches generate an instant “bolus” of H<sub>2</sub>S rather than release H<sub>2</sub>S in a slow and sustained manner, as occurs enzymatically from CSE and CBS and as would be expected to occur in intact cells/tissues.


Therefore, we investigated whether the effects of bolus H<sub>2</sub>S (generated by NaHS) or slow and sustained H<sub>2</sub>S release (*via* GYY4137) elicited differential responsiveness to LPS in murine RAW264.7 macrophages. In contrast to NaHS, the present data reveal a very much slower and sustained release of H<sub>2</sub>S, again measured by using an H<sub>2</sub>S-selective probe, from incubated GYY4137. The present study serves, (a) to highlight important differences in the effect of these two H<sub>2</sub>S donors on the inflammatory response of cultured macrophages to LPS, and (b) to shed new light on the possible mechanism(s) underlying the recently reported antiinflammatory effect of the slow-releasing H<sub>2</sub>S donor GYY4137 in LPS-evoked endotoxin shock *in vivo* (12).



**FIG. 5.** Effect of GYY4137 on phosphorylation of ATF-2 (A) and HSP-27 (B) in LPS (1 µg/ml)-treated (24 h) RAW 264.7 cells. Saline-treated control cells are shown by the grey column. Results show ratio of phosphorylated to nonphosphorylated product and are expressed as mean ± SEM;  $n = 5$ ; \* $p < 0.05$  (c.f. LPS group);  $^+p < 0.05$  (c.f. saline group); ANOVA plus *post hoc* Tukey test.

GYY4137 consistently inhibited LPS-evoked formation of PGE<sub>2</sub>, \*NO (as measured by NO<sub>2</sub><sup>-</sup> accumulation), TNF- $\alpha$ , IL-1 $\beta$ , IL-6, and consistently augmented LPS-induced formation of IL-10 in cultured RAW 264.7 cells. In contrast, the effect of NaHS was very much less consistent, with a biphasic (inhibition at a concentration of 200 µM; no action at higher concentrations) effect on LPS-induced PGE<sub>2</sub> and NO<sub>2</sub><sup>-</sup> formation and no statistically significant inhibitory effect on the evoked biosynthesis of either TNF- $\alpha$  or IL-1 $\beta$ . Indeed, at the highest concentration studied, NaHS actually promoted LPS-evoked cytokine generation in these cells. Whether such an effect might contribute to the reported proinflammatory effect of this H<sub>2</sub>S donor (*e.g.*, 9) is not yet clear.

Decomposed GYY4137 (left at room temperature for 5 days) did not affect LPS-induced biosynthesis of either PGE<sub>2</sub> or NO<sub>2</sub><sup>-</sup>, demonstrating that the effects of GYY4137 observed in this study were largely due to released H<sub>2</sub>S. Furthermore, GYY4137 caused a concentration-dependent inhibition of the LPS-induced NF- $\kappa$ B activation in RAW 264.7 cells, together



**FIG. 6.** Effect of NaHS (black columns) and GYY4137 (open columns) on activation of NF- $\kappa$ B in LPS (1  $\mu$ g/ml)-treated (24 h) RAW 264.7 cells. Results show relative light units (RLU) and are expressed as mean  $\pm$  SEM;  $n = 5$ ; \* $p < 0.05$  (c.f. LPS group); + $p < 0.05$  (c.f. saline group); ANOVA plus *post hoc* Tukey test.

with a concentration-dependent reduction of the phosphorylation of both ATF-2 and HSP-27. In contrast, the effects of NaHS on NF- $\kappa$ B activation was biphasic, in that lower concentrations increased activation, but higher concentrations were inhibitory (500  $\mu$ M or greater). Neither GYY4137 nor NaHS at the highest concentration used in this study (1,000  $\mu$ M) affected cell viability and thus the observed effect of these H<sub>2</sub>S donors on macrophage inflammatory mediator release are unlikely to be secondary to any toxic effect of H<sub>2</sub>S, at least under the experimental conditions used in the present work.

We previously reported that GYY4137 reduced LPS-evoked hypotension and organ damage while reducing plasma cytokine levels in the rat *in vivo* (12). The present data confirm that GYY4137 inhibits LPS-induced release of inflammatory mediators (*i.e.*, PGE<sub>2</sub>, \*NO, TNF- $\alpha$ , and IL1 $\beta$ ) from macrophages *in vitro* and show for the first time that this H<sub>2</sub>S donor increases the release of antiinflammatory IL-10 under the same experimental conditions. The finding that GYY4137 also inhibited LPS-induced NF- $\kappa$ B activation is consistent with previous reports in the literature suggesting an inhibitory effect of H<sub>2</sub>S on transcription *via* NF- $\kappa$ B. For example, H<sub>2</sub>S (derived from NaHS) inhibited NF- $\kappa$ B activation in LPS-challenged RAW 264.7 macrophages maintained in culture (16), whereas exposure of rats to gaseous H<sub>2</sub>S reduced brain (cortical) NF- $\kappa$ B mRNA (5). The H<sub>2</sub>S donor drug, *S*-diclofenac, also reduced liver NF- $\kappa$ B activation in LPS-injected rats (11). In addition, H<sub>2</sub>S reduced kidney NF- $\kappa$ B activation in a rat model of renal ischemia/reperfusion injury (22). Other potential H<sub>2</sub>S donors, such as the garlic constituent, diallylsulfide, also inhibit NF- $\kappa$ B activation in primary cultures of human articular chondrocytes (8) and in lung fibrosis induced by bleomycin in rats (7).

In contrast, we show here that only a high concentration of NaHS inhibits NF- $\kappa$ B activation. Indeed, at lower concentrations of NaHS (*e.g.*, 100 and 200  $\mu$ M), a small but significant activation of NF- $\kappa$ B is apparent. Interestingly, a similar acti-

vating effect of this H<sub>2</sub>S donor was reported in an interferon- $\gamma$  (IFN- $\gamma$ ) – primed human monocytic cell line (U937), most likely by rapid degradation of I $\kappa$ B $\alpha$  (31). It is paradoxical that NaHS (1 mM) inhibits NF- $\kappa$ B activation in RAW 264.7 cells but promotes the LPS-evoked formation of TNF- $\alpha$  and IL-1 $\beta$  without significantly altering PGE<sub>2</sub> or NO<sub>2</sub><sup>-</sup> generation. These data suggest that NaHS at such high concentrations may also be able to affect the function of transcription factors other than NF- $\kappa$ B. In this respect, we previously reported that administration of the H<sub>2</sub>S donor, *S*-diclofenac, reduced liver AP-1 activation in LPS-injected rats. An identical effect also was observed with the parent compound, diclofenac (11), which would argue against a direct effect of H<sub>2</sub>S on AP-1. However, other H<sub>2</sub>S donors, such as diallylsulfide and diallytrisulfide, have both been reported to increase the DNA-binding activity of AP-1 in rat epithelial clone 9 cells (23). Certainly, the present data suggest that the effect of NaHS on NF- $\kappa$ B activation under these experimental conditions is biphasic, and further experiments are required to determine whether high concentrations of NaHS are able to affect other transcription factors in these cells.

To the best of our knowledge, no other reports exist of the effect of H<sub>2</sub>S donors on either ATF-2 or HSP-27. As such, both should now be considered as potential targets for GYY4137/H<sub>2</sub>S. In this respect, HSP-27 was recently implicated as a regulator of the increased expression of both cyclooxygenase-2 (COX-2) and IL-6 in inflammatory cells exposed to LPS (1), most probably by modulating NF- $\kappa$ B signaling (20), whereas ATF-2 is a member of the ATF/cAMP-response element-binding protein family, which play an important role in the cellular stress response. Interestingly, TNF- $\alpha$  is one of the major target genes for ATF-2 (24). Growing evidence suggests that ATF-2 plays an important role in the stress response, cell growth and differentiation, as well as the immune response, and the finding that it is targeted by GYY4137 is potentially of wider interest.

An important feature of the present study is the finding that, although GYY4137 consistently reduced LPS-evoked inflammatory mechanisms in RAW 264.7 cells, the response to NaHS was less consistent. It should perhaps be noted that other authors have detected an effect of NaHS on LPS-evoked inflammatory changes (*e.g.*, NO<sub>2</sub><sup>-</sup> formation, iNOS expression, and NF- $\kappa$ B activation) in RAW 264.7 cells in culture (16). The reason for the discrepancy between the two studies is not clear. However, important differences exist in the experimental conditions used. For example, we incubated cells with either GYY4137 or NaHS concurrent with LPS for 24 h, whereas in the previous study, macrophages were preincubated with NaHS for 12 h before addition of LPS, and further incubation for an additional 18 h. Bearing in mind the transient stability of NaHS in culture medium, it is likely that the time course of exposure of cells to NaHS will be a very important factor in determining the effect of H<sub>2</sub>S on LPS-induced inflammatory mediator release under these experimental conditions. With this in mind, it is interesting that, in the present experiments, H<sub>2</sub>S was detectable in the culture medium at the end of the incubation period when macrophages were incubated with GYY4137 but not with an equivalent concentration of NaHS.

We previously reported that GYY4137 releases H<sub>2</sub>S slowly (*i.e.*, over a period of several hours) in aqueous buffer and produces a sustained increase in plasma H<sub>2</sub>S concentration in

the anesthetized rat after parenteral injection (13). When dissolved in water, H<sub>2</sub>S rapidly forms the hydrosulfide anion (HS<sup>-</sup>), which enters into an equilibrium with H<sup>+</sup> to yield H<sub>2</sub>S. Consequently, GYY4137 is best considered a “slow releasing” H<sub>2</sub>S donor. In contrast, release of H<sub>2</sub>S from NaHS is rapid. Indeed, NaHS injection did not result in measurable increase in plasma H<sub>2</sub>S in the anesthetized rat. Thus, NaHS is considered a “fast releasing” donor of this gas (13). With this in mind, it is conceivable that RAW 264.7 cells were exposed to very much higher concentrations of H<sub>2</sub>S but for a very much shorter time in the presence of NaHS (c.f. GYY4137).

In conclusion, the effect of H<sub>2</sub>S on inflammatory mechanisms in isolated macrophages seems to be dependent to a large extent on the choice of H<sub>2</sub>S donor. It is known that different donors release H<sub>2</sub>S at different rates. It is likely that both the absolute concentration of this gas and the time course of its presence after provocation of an inflammatory response by LPS, in this instance, are critical. Drugs that release small amounts of H<sub>2</sub>S over an extended time appear to be more effective than drugs that release larger amounts of the gas over a shorter time. This should perhaps be borne in mind in the search for novel H<sub>2</sub>S donors with potential anti-inflammatory activity in the clinic. Furthermore, the anti-inflammatory effect of GYY4137, which we previously identified in intact rats, is likely to be dependent on inhibition of transcription through the NF- $\kappa$ B pathway. The possibility that GYY4137 may also interfere with both ATF-2 and HSP-27 is an intriguing one and warrants further study.

### Acknowledgments

We are grateful to the Arthritis Research Campaign (MP/8471, U.K.) and the Northcott Devon Medical Foundation for their continued and generous research support.

### Author Disclosure Statement

No competing financing interests exist.

### References

- Alford KA, Glennie S, Turrell BR, Rawlinson L, Saklatvala J, and Dean JL. Heat shock protein 27 functions in inflammatory gene expression and transforming growth factor-beta-activated kinase-1 (TAK1)-mediated signaling. *J Biol Chem* 282: 6232–6241, 2007.
- Bhatia M, Wong FL, Fu D, Lau HY, Moochhala SM, and Moore PK. Role of hydrogen sulphide in acute pancreatitis in the mouse and rat. *FASEB J* 19: 623–625, 2004.
- Chang L, Geng B, Yu F, Zhao J, Jiang H, Du J, and Tang C. Hydrogen sulfide inhibits myocardial injury induced by homocysteine in rats. *Amino Acids* 34: 573–585, 2008.
- Collin M, Anuar F, Murch O, Bhatia M, Moore PK, and Thiemermann C. Inhibition of endogenous hydrogen sulfide formation reduces the organ injury caused by endotoxemia. *Br J Pharmacol* 146: 498–505, 2005.
- Florian B, Vintilescu R, Balseanu AT, Buga AM, Grisk O, Walker LC, Kessler C, and Popa-Wagner A. Long-term hypothermia reduces infarct volume in aged rats after focal ischemia. *Neurosci Lett* 438: 180–185, 2008.
- Geng B, Chang L, Pan C, Qi, Y, Zhao J, Pang Y, Du J, and Tang C. Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. *Biochem Biophys Res Commun* 318: 756–763, 2004.
- Kalayarasan S, Sriram N, and Sudhandiran G. Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: critical role of iNOS, NF-kappaB, TNF-alpha and IL-1 beta. *Life Sci* 82: 1142–1153, 2008.
- Lee HS, Lee CH, Tsai HC, and Salter DM. Inhibition of cyclooxygenase 2 expression by diallyl sulfide on joint inflammation induced by urate crystal and IL-1beta. *Osteoarthritis Cartilage* 17: 91–99, 2009.
- Li L, Bhatia M, Zhu YZ, Zhu Y, Ramnath RD, Wang ZJ, Anuar F, Whiteman M, Salto-Tellez M, and Moore PK. Hydrogen sulfide is a novel mediator of endotoxic shock. *FASEB J* 119: 1196–1198, 2005.
- Li L, Hsu A, and Moore PK. Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and in inflammation: a tale of three gases! *Pharmacol Ther* 123: 386–400, 2009.
- Li L, Rossoni G, Sparatore A, Lee LC, Del Soldato P, and Moore PK. Anti-inflammatory and gastrointestinal sparing activity of a novel H<sub>2</sub>S-releasing diclofenac agent: new insights into the biological roles of H<sub>2</sub>S. *Free Radic Biol Med* 42: 706–719, 2006.
- Li L, Salto-Tellez M, Tan CH, Whiteman M, and Moore PK. GYY4137, a novel hydrogen sulfide-releasing molecule, protects against endotoxic shock in the rat. *Free Radic Biol Med* 47: 103–113, 2009.
- Li L, Whiteman M, Guan Y, Neo KL, Cheng Y, Lee SW, Zhao Y, Baskar R, Tan CH, and Moore PK. Characterisation of a novel, water soluble hydrogen sulfide releasing molecule (GYY4137): new insights into the biology of hydrogen sulphide. *Circulation* 117: 2351–2360, 2008.
- Mok YYP, Atan MS, Cheung YP, Wang ZJ, Bhatia M, Moochhala S, and Moore PK. Role of hydrogen sulphide in haemorrhagic shock in the rat: protective effect of inhibitors of hydrogen sulphide biosynthesis. *Br J Pharmacol* 143: 881–889, 2004.
- Muzzaffar S, Shukla N, Bond M, Newby AC, Angelini GD, Sparatore A, Del Soldato P, and Jeremy J. Exogenous hydrogen sulfide inhibits superoxide formation, NOX-1 expression and Rac<sub>1</sub> activity in human vascular smooth muscle cells. *J Vasc Res* 45: 521–528, 2008.
- Oh GS, Pae HO, Lee BS, Kim BN, Kim JM, Kim HR, Jeon SB, Jeon WK, Chae HJ, and Chung HT. Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. *Free Radic Biol Med* 41: 106–119, 2006.
- Rose P, Won YK, Ong CN, and Whiteman M. Beta-phenylethyl and 8-methylsulphonyloctyl isothiocyanates, constituents of watercress, suppress LPS induced production of nitric oxide and prostaglandin E<sub>2</sub> in RAW 264.7 macrophages. *Nitric Oxide* 12: 237–243, 2005.
- Sidhapuriwala J, Li L, Sparatore A, Moore PK, and Bhatia M. Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative, on carrageenan-induced hindpaw oedema formation in the rat. *Eur J Pharmacol* 569: 149–154, 2007.
- Stipanuk MH. Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. *Annu Rev Nutr* 24: 539–577, 2004.
- Sur R, Lyte PA, and Southall MD. Hsp27 regulates pro-inflammatory mediator release in keratinocytes by modulating NF-kappaB signaling. *J Invest Dermatol* 128: 1116–1122, 2008.
- Szabo C. Hydrogen sulphide and its therapeutic potential. *Nat Rev Drug Disc* 6: 917–935, 2007.

22. Tripatara P, Patel NS, Collino M, Gallicchio M, Kieswich J, Castiglia S, Benetti E, Stewart KN, Brown PA, Yaqoob MM, Fantozzi R, and Thiemermann C. Generation of endogenous hydrogen sulfide by cystathionine gamma-lyase limits renal ischemia/reperfusion injury and dysfunction. *Lab Invest* 88: 1038–1048, 2008.
23. Tsai CW, Chen HW, Yang JJ, Sheen LY, and Lii CK. Diallyl disulfide and diallyl trisulfide up-regulate the expression of the pi class of glutathione S-transferase via an AP-1-dependent pathway. *J Agric Food Chem* 55: 1019–1026, 2007.
24. Tsai EY, Jain J, Pesevanto PA, Rao A, and Goldfield AE. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. *Mol Cell Biol* 16: 459–467, 1996.
25. Whiteman M, Armstrong JS, Chu SH, Jia-Ling S, Wong BS, Cheung NS, Halliwell B, and Moore PK. The novel neuro-modulator hydrogen sulfide: an endogenous peroxynitrite “scavenger”? *J Neurochem* 90: 765–768, 2004.
26. Whiteman M, Cheung NS, Zhu YZ, Chu SH, Siau JL, Wong BS, Armstrong JS, and Moore PK. Hydrogen sulfide: a novel mediator of hypochlorous acid mediated oxidative damage in the brain. *Biochem Biophys Res Commun* 326: 794–798, 2004.
27. Whiteman M, Spencer JP, Zhu YZ, Armstrong JS, and Schantz JT. Peroxynitrite-modified collagen-II induces p38/ERK and NF-kappaB-dependent synthesis of prostaglandin E2 and nitric oxide in chondrogenically differentiated mesenchymal progenitor cells. *Osteoarthritis Cartilage* 4: 460–470, 2006.
28. Whiteman M and Moore PK. Hydrogen sulfide and the vasculature: a novel vasculoprotective entity and regulator of nitric oxide bioavailability? *J Cell Mol Med* 13: 488–507, 2009.
29. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, Meng Q, Mustafa AK, Mu W, Zhang S, Snyder SH, and Wang R. H<sub>2</sub>S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. *Science* 322: 587–590, 2008.
30. Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, and Wallace JL. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. *FASEB J* 20: 2118–2120, 2006.
31. Zhi L, Ang AD, Zhang H, Moore PK, and Bhatia M. Hydrogen sulfide induces the synthesis of proinflammatory

cytokines in human monocyte cell line U937 via the ERK-NF-kappaB pathway. *J Leukoc Biol* 81: 1322–1332, 2007.

Address correspondence to:

Prof. Philip Moore  
 Pharmaceutical Science Research Division  
 King's College  
 University of London  
 150 Stamford Street  
 Franklin Wilkins Building  
 London SE1 9NH  
 United Kingdom

E-mail: phillip.moore@kcl.ac.uk

Date of first submission to ARS Central, September 15, 2009;  
 date of acceptance, September 19, 2009.

#### Abbreviations Used

ATF-2 = activating transcription factor-2  
 CBS = cystathionine  $\beta$  synthetase  
 CSE = cystathionine  $\gamma$  lyase  
 GYY4137 = morpholin-4-ium 4-methoxyphenyl  
 (morpholino) phosphinodithioate  
 H<sub>2</sub>S = hydrogen sulfide  
 HSP-27 = heat-shock protein-27  
 IL-1 $\beta$  = interleukin-1 beta  
 LPS = lipopolysaccharide  
 MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-  
 diphenyltetrazolium bromide  
 NaHS = sodium hydrosulfide  
 NF- $\kappa$ B = nuclear factor  $\kappa$ B  
 •NO = nitric oxide  
 NO<sub>2</sub><sup>-</sup> = nitrite  
 PGE<sub>2</sub> = prostaglandin E<sub>2</sub>  
 TNF $\alpha$  = tumor necrosis factor alpha